No relevant news for Apogee Therapeutics Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 Jan 26
Source: 8-K
Apogee Therapeutics Inc. has experienced a significant price drop of 10.07%, hitting a 20-day low.
However, there is no specific news related to Apogee Therapeutics that could explain this decline, indicating a potential sector rotation as the broader market, including the Nasdaq-100 and S&P 500, shows slight gains.
This price movement may reflect broader market dynamics rather than company-specific issues, suggesting investors should monitor market trends closely.
Analyst Views on APGE
Wall Street analysts forecast APGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APGE is 102.50 USD with a low forecast of 70.00 USD and a high forecast of 137.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 70.690
Low
70.00
Averages
102.50
High
137.00
Current: 70.690
Low
70.00
Averages
102.50
High
137.00
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
